Reprogramming T lymphocytes for melanoma adoptive immunotherapy by T-cell receptor gene transfer with lentiviral vectors.
about
Chemokine-Derived Peptides: Novel Antimicrobial and Antineoplasic AgentsPSMA-specific CAR-engineered T cells eradicate disseminated prostate cancer in preclinical modelsT-cell receptor gene therapy--ready to go viral?A shift from cell cultures to creatures: in vivo imaging of small animals in experimental regenerative medicine.Kinetic phases of distribution and tumor targeting by T cell receptor engineered lymphocytes inducing robust antitumor responses.Optogenetic control of chemokine receptor signal and T-cell migration.A BARF1-specific mAb as a new immunotherapeutic tool for the management of EBV-related tumors.Enhanced transduction and replication of RGD-fiber modified adenovirus in primary T cellsRebalancing immune specificity and function in cancer by T-cell receptor gene therapy.Differential down-modulation of HLA class I and II molecule expression on human tumor cell lines upon in vivo transfer.Antitumor activity from antigen-specific CD8 T cells generated in vivo from genetically engineered human hematopoietic stem cells.TCR hypervariable regions expressed by T cells that respond to effective tumor vaccines.Transduction of tumor-specific T cells with CXCR2 chemokine receptor improves migration to tumor and antitumor immune responses.Bi-specific TCR-anti CD3 redirected T-cell targeting of NY-ESO-1- and LAGE-1-positive tumors.Anti-melanoma activity of T cells redirected with a TCR-like chimeric antigen receptorTumour immunogenicity, antigen presentation and immunological barriers in cancer immunotherapy.Genetic redirection of T cells for cancer therapy.Advances in the field of lentivector-based transduction of T and B lymphocytes for gene therapy.Requisite considerations for successful adoptive immunotherapy with engineered T-lymphocytes using tumor antigen-specific T-cell receptor gene transfer.Gene therapy for mesothelioma.Lentiviral vectors for cancer immunotherapy and clinical applicationsAdoptive cellular therapy of cancer: exploring innate and adaptive cellular crosstalk to improve anti-tumor efficacy.T-cell receptor-engineered T cells for cancer treatment: current status and future directions.Mesothelin as a target for chimeric antigen receptor-modified T cells as anticancer therapy.Melanoma Immunotherapy in Mice Using Genetically Engineered Pluripotent Stem Cells.Augmented adenovirus transduction of murine T lymphocytes utilizing a bi-specific protein targeting murine interleukin 2 receptor.Impact of γ-chain cytokines on EBV-specific T cell cultures.Influenza virus-specific TCR-transduced T cells as a model for adoptive immunotherapy.Adoptive cell transfer of T-cell receptor-engineered lymphocytes: lessons from recent modeling.Clinical use of lentiviral vectors.Chemokine Receptors and Exercise to Tackle the Inadequacy of T Cell Homing to the Tumor Site
P2860
Q26830743-AD6CD6CC-441F-4111-AB04-64028B271FC2Q27339832-63110020-00D3-4173-A56D-5D7DDA14C8D2Q28081611-7C36791A-AAD6-42C8-AF5A-A0263E2BF4C1Q30461932-D159F5F3-2DDF-4651-95E7-EE4E947329D2Q30496118-F609BA84-0A57-44FB-B8E8-55B5853CFE75Q30579021-1C1A8F55-0C4A-49BB-9ED8-51CE9F56D109Q33632095-83B87E3A-4034-4641-B60F-3BF709B034B1Q33862517-573912F7-F338-49B8-A6D8-B6687D945383Q34084756-5DAE194F-160F-4CAE-A48C-458C56CAC71CQ35402927-3A7831A9-8132-4B1D-BE01-0CBF8B65D458Q35650970-0FD2C8B8-AED5-4F36-BEFF-90D8781D2327Q36137249-44BB96CD-EF04-4F8B-857F-EBC4C1DE4B12Q36333963-186A2CB8-BAD3-4A53-8C67-CBCFB92837F4Q36759301-EB3FAFD5-7B87-426A-82F3-D640CA5F82CEQ37434176-49CB26B8-0331-40C3-92CD-C24450494E33Q37635491-F43E7AB6-7058-43CA-8A22-8797C2E2B4D1Q37697337-88ACC79F-AD37-4A26-83B8-A6648903E8E8Q37782256-D2B786E7-042B-47B4-8B4B-9596E0318404Q37854072-5BCD576A-1EDD-439E-849E-3398A90AF583Q37868973-C5AE98F4-2AA6-4348-A609-FD6D91642418Q38147100-1D30276F-EF24-4AD2-85C8-3402AC4EBA43Q38258842-BD9B2F00-4F01-461E-BD54-1F6911E13846Q38767662-80869274-3873-4628-BF77-0C5E0B4A97ABQ38773361-C4D877EB-B739-4D35-AA6D-225197AA9517Q38802594-6DC3286E-2EC9-449D-BA13-E8FD60DF4B08Q39113283-C32026DF-0EFE-44C1-B7CB-379AF0C184B4Q41148685-A0631515-5EC5-45C5-A099-6AD557B2C0B9Q43964931-C91AE295-DC04-4644-B8A4-BD7BD5F0358DQ51773657-003332BD-BF30-4828-99E9-9E74AC7D0D58Q52589095-3AE95F3A-B98F-4200-8891-83CE8D0AEA97Q58768316-358851FC-23D2-4BA4-8E01-83E10C869247
P2860
Reprogramming T lymphocytes for melanoma adoptive immunotherapy by T-cell receptor gene transfer with lentiviral vectors.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
Reprogramming T lymphocytes fo ...... nsfer with lentiviral vectors.
@en
Reprogramming T lymphocytes fo ...... nsfer with lentiviral vectors.
@nl
type
label
Reprogramming T lymphocytes fo ...... nsfer with lentiviral vectors.
@en
Reprogramming T lymphocytes fo ...... nsfer with lentiviral vectors.
@nl
prefLabel
Reprogramming T lymphocytes fo ...... nsfer with lentiviral vectors.
@en
Reprogramming T lymphocytes fo ...... nsfer with lentiviral vectors.
@nl
P2093
P50
P1433
P1476
Reprogramming T lymphocytes fo ...... nsfer with lentiviral vectors.
@en
P2093
Anna Merlo
Maria Rondina
Ralph A Willemsen
Reno Debets
Sara Bobisse
P304
P356
10.1158/0008-5472.CAN-09-0494
P407
P577
2009-12-01T00:00:00Z